A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(18 sites)

United States

Research Site, Gilbert, Arizona

Research Site, Duarte, California

Research Site, Newport Beach, California

Research Site, Santa Monica, California

Research Site, Jacksonville, Florida

Research Site, Miami, Florida

Research Site, Tampa, Florida

Research Site, Boston, Massachusetts

Research Site, New Brunswick, New Jersey

Research Site, New York, New York

Research Site, Charlotte, North Carolina

Research Site, Winston-Salem, North Carolina

Research Site, Portland, Oregon

Research Site, Pittsburgh, Pennsylvania

Research Site, Nashville, Tennessee

Research Site, Houston, Texas

Research Site, Round Rock, Texas

Research Site, Milwaukee, Wisconsin